<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40741226</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2950-5410</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of pediatrics. Clinical practice</Title><ISOAbbreviation>J Pediatr Clin Pract</ISOAbbreviation></Journal><ArticleTitle>Five-Year Experience of Etanercept as Adjunct to Intravenous Immunoglobulin for Kawasaki Disease with Coronary Artery Involvement.</ArticleTitle><Pagination><StartPage>200165</StartPage><MedlinePgn>200165</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">200165</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpedcp.2025.200165</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The Etanercept as Adjunctive Treatment for Acute Kawasaki Disease trial was a phase 3, placebo-controlled, randomized trial that evaluated etanercept use for acute Kawasaki disease (KD). Trial data suggest improved coronary artery aneurysm metrics with etanercept compared to placebo. This report summarizes a single center continued experience with etanercept for KD presenting with coronary artery aneurysms (<i>z</i> score &#x2265;2.5).</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="UNASSIGNED">Etanercept at 3 weekly doses, first given as adjuvant to Intravenous Immunoglobulin, is given to all children admitted with acute KD and coronary artery aneurysm(s). Chart review was performed for 37 children who received at least 1 dose of etanercept for this indication to evaluate for side effects, compliance, and coronary artery outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 37 children, 95% and 92% completed a 2nd and 3rd dose of etanercept as outpatient. No serious adverse events were observed. Of the 30 children with mild or moderate coronary artery dilation (<i>z</i> score &#x2265;2.5 but &lt;10), 77% regressed to <i>z</i> score &lt;2.5 by 6 weeks and 97% by 2 years. In 7 children that presented with giant aneurysm(s) (<i>z</i> score &#x2265;10), 71% and 86% regressed to a <i>z</i> score &lt;10 at 6 weeks and 6 months, respectively, allowing discontinuation of anticoagulation.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Etanercept as intensification therapy for KD with coronary artery aneurysms can be delivered safely and with good compliance. This report suggests benefit in preventing long-term persistence of severe and any coronary artery disease.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Seattle Children's Hospital, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sagiv</LastName><ForeName>Eyal</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Seattle Children's Hospital, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Aaron K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Seattle Children's Hospital, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portman</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Seattle Children's Hospital, Seattle, WA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pediatr Clin Pract</MedlineTA><NlmUniqueID>9918769578606676</NlmUniqueID><ISSNLinking>2950-5410</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword><Keyword MajorTopicYN="N">aneurysm</Keyword><Keyword MajorTopicYN="N">etanercept</Keyword><Keyword MajorTopicYN="N">intensification</Keyword><Keyword MajorTopicYN="N">kawasaki</Keyword><Keyword MajorTopicYN="N">vasculitis</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>12</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40741226</ArticleId><ArticleId IdType="pmc">PMC12309919</ArticleId><ArticleId IdType="doi">10.1016/j.jpedcp.2025.200165</ArticleId><ArticleId IdType="pii">S2950-5410(25)00027-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Newburger J.W., Takahashi M., Burns J.C. Kawasaki disease. J Am Coll Cardiol. 2016;67:1738&#x2013;1749.</Citation><ArticleIdList><ArticleId IdType="pubmed">27056781</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrindle B.W., Rowley A.H., Newburger J.W., Burns J.C., Bolger A.F., Gewitz M., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart association. Circulation. 2017;135:e927&#x2013;e999.</Citation><ArticleIdList><ArticleId IdType="pubmed">28356445</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman S.T., Rowley A.H. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol. 2015;11:475&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">25907703</ArticleId></ArticleIdList></Reference><Reference><Citation>Noval R.M., Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol. 2020;16:391&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250272</ArticleId><ArticleId IdType="pubmed">32457494</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara T., Furukawa S., Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990;56:29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">2113446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Liu L., Huang X., Tian J. Insights into coronary artery lesions in Kawasaki disease. Front Pediatr. 2020;8:493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477115</ArticleId><ArticleId IdType="pubmed">32984207</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Li D.E., Hu M., Huang H., Xu S., Li H. Red blood cell distribution width and tumor necrosis factor-&#x3b1; for the early prediction of coronary artery lesion in Kawasaki disease: a retrospective study. Eur J Pediatr. 2022;181:903&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">34494160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Liao J., Xiang L., Zhang S., Yan Y. Current knowledge of TNF-&#x3b1; monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review. Front Immunol. 2023;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10626541</ArticleId><ArticleId IdType="pubmed">37936712</ArticleId></ArticleIdList></Reference><Reference><Citation>Portman M.A., Dahdah N.S., Slee A., Olson A.K., Choueiter N.F., Soriano B.D., et al. Etanercept with IVIg for acute Kawasaki disease: a randomized controlled trial. Pediatrics. 2019;143</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6564061</ArticleId><ArticleId IdType="pubmed">31048415</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagiv E., Slee A., Buffone A., Choueiter N.F., Dahdah N.S., Portman M.A. Etanercept with IVIg for acute Kawasaki disease: a long-term follow-up on the EATAK trial. Cardiol Young. 2023;33:613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">35545881</ArticleId></ArticleIdList></Reference><Reference><Citation>Stirnadel-Farrant H.A., Galwey N., Bains C., Yancey C., Hunt C.M. Children's liver chemistries vary with age and gender and require customized pediatric reference ranges. Regul Toxicol Pharmacol. 2015;73:349&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">26190302</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins V., Tahmasebi H., Bohn M.K., Hall A., Adeli K. CALIPER hematology reference standards (II) Am J Clin Pathol. 2020;154:342&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403758</ArticleId><ArticleId IdType="pubmed">32525543</ArticleId></ArticleIdList></Reference><Reference><Citation>Jone P.N., Tremoulet A., Choueiter N., Dominguez S.R., Harahsheh A.S., Mitani Y., et al. American Heart association rheumatic fever, endocarditis, and Kawasaki disease committee of the council on lifelong congenital Heart disease and Heart health in the young; council on cardiovascular and stroke nursing; council on cardiovascular radiology and intervention; and council on clinical cardiology. Update on diagnosis and management of Kawasaki disease: a scientific statement from the American Heart association. Circulation. 2024;150:e481&#x2013;e500.</Citation><ArticleIdList><ArticleId IdType="pubmed">39534969</ArticleId></ArticleIdList></Reference><Reference><Citation>Son M.B.F., Gauvreau K., Tremoulet A.H., Lo M., Baker A.L., de Ferranti S., et al. Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a North American population. J Am Heart Assoc. 2019;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6585355</ArticleId><ArticleId IdType="pubmed">31130036</ArticleId></ArticleIdList></Reference><Reference><Citation>Benovoy M., Dionne A., McCrindle B.W., Manlhiot C., Ibrahim R., Dahdah N. Deep Learning-based approach to automatically assess coronary distensibility following Kawasaki disease. Pediatr Cardiol. 2021;43:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">34854943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H., Sugimura T., Akagi T., Sato N., Hashino K., Maeno Y., et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">8822996</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrindle B.W., Manlhiot C., Newburger J.W., Harahsheh A.S., Giglia T.M., Dallaire F., et al. Medium-term complications associated with coronary artery aneurysms after Kawasaki disease: a study from the international Kawasaki disease Registry. J Am Heart Assoc. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792232</ArticleId><ArticleId IdType="pubmed">32750313</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellicini I., Bainto E., Shimizu C., Burns J.C., Tremoulet A.H. Cyclosporine treatment in patients with Kawasaki Disease and coronary artery aneurysms or treatment resistance. J Pediatr. 2025;279</Citation><ArticleIdList><ArticleId IdType="pubmed">39863079</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman K.G., Gauvreau K., Baker A., Son M.B., Sundel R., Dionne A., et al. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis. Arch Dis Child. 2021;106:247&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">32943389</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremoulet A.H., Jain S., Jaggi P., Jimenez-Hernandez S., Pancheri J.M., Sun X., et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383:1731&#x2013;1738.</Citation><ArticleIdList><ArticleId IdType="pubmed">24572997</ArticleId></ArticleIdList></Reference><Reference><Citation>Jone P.N., Anderson M.S., Mulvahill M.J., Heizer H., Glod&#xe9; M.P., Dominguez S.R. Infliximab plus Intravenous Immunoglobulin (IVIG) versus IVIG alone as initial therapy in children with Kawasaki disease presenting with coronary artery lesions: is dual therapy more effective? Pediatr Infect Dis J. 2018;37:976&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6093799</ArticleId><ArticleId IdType="pubmed">29461447</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata K., Bainto E.V., Sun X., Jain S., Dummer K.B., Burns J.C., et al. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis. Arch Dis Child. 2023;108:833&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10511975</ArticleId><ArticleId IdType="pubmed">37258054</ArticleId></ArticleIdList></Reference><Reference><Citation>Dionne A., Burns J.C., Dahdah N., Tremoulet A.H., Gauvreau K., de Ferranti S.D., et al. Treatment intensification in patients with Kawasaki Disease and coronary aneurysm at diagnosis. Pediatrics. 2019;143</Citation><ArticleIdList><ArticleId IdType="pubmed">31048414</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>